Conformationally restricted P13K and mTOR inhibitors
US9556203B2 · kind B2 · utility
7Cited by
0References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 3, 2014 |
| Grant date | Jan 31, 2017 |
| Priority date | — |
| Expiry date | Oct 3, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to novel phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor compounds of formula (I) and (II), which are conformationally restricted, and for which the meaning of the substituents are listed in the description. Preferred compounds are those wherein X isoxygen, R1 is morpholino and R2 is substituted phenyl or heteroaryl. These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.